Advertisement
Guidelines and Guidance

Guidelines and Guidance The Guidelines and Guidance section contains advice on conducting and reporting medical research.

See all article types »

Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): Explanation and Elaboration

  • Douglas G. Altman mail,

    doug.altman@csm.ox.ac.uk

    Affiliation: Centre for Statistics in Medicine, University of Oxford, Oxford, United Kingdom

    X
  • Lisa M. McShane,

    Affiliation: US National Cancer Institute, Bethesda, Maryland, United States of America

    X
  • Willi Sauerbrei,

    Affiliation: Institut fuer Medizinische Biometrie und Medizinische Informatik, Universitaetsklinikum Freiburg, Freiburg, Germany

    X
  • Sheila E. Taube

    Affiliation: ST-Consulting, Bethesda, Maryland, United States of America

    X
  • Published: May 29, 2012
  • DOI: 10.1371/journal.pmed.1001216

About the Authors

Douglas G. Altman
Centre for Statistics in Medicine, University of Oxford, Oxford, United Kingdom
Lisa M. McShane
US National Cancer Institute, Bethesda, Maryland, United States of America
Willi Sauerbrei
Institut fuer Medizinische Biometrie und Medizinische Informatik, Universitaetsklinikum Freiburg, Freiburg, Germany
Sheila E. Taube
ST-Consulting, Bethesda, Maryland, United States of America

Corresponding Author

Email: doug.altman@csm.ox.ac.uk

Competing Interests

All authors declare no competing interests.

Author Contributions

Wrote the first draft of the manuscript: DGA LMM WS SET. Contributed to the writing of the manuscript: DGA LMM WS SET. ICMJE criteria for authorship read and met: DGA LMM WS SET. Agree with manuscript results and conclusions: DGA LMM WS SET.